
Opinion|Videos|September 18, 2024
Evaluating Imaging Agents in Oligometastatic Prostate Cancer: A Comparative Analysis of Gallium-Based and Non-Gallium-Based Options
Author(s)Jaideep S. Sohi, MD, Jeremie Calais, MD
Medical experts conduct a comparative assessment of gallium-based and non-gallium-based imaging agents to determine their efficacy in detecting and characterizing oligometastatic prostate cancer.
Advertisement
Video content above is prompted by the following:
- Can you discuss the advantages and limitations of different imaging agents commonly used in identifying oligometastatic disease in prostate cancer, such as gallium-based agents versus non-gallium-based agents?
- Are you aware of any differences in lesion detection rates or staging accuracy between gallium vs non- gallium-based PET imaging agents?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
New Ultrasound Contrast Delivery System Garners FDA 510(k) Clearance
2
Molecular Imaging in Focus: PSMA PET Pioneer Martin Pomper, MD, PhD Traces PSMA’s Origins and the Path Ahead for Theranostics in Prostate Cancer
3
Breast MRI Study Reveals 29 Percent Reduction in Scan Time with Deep Learning Reconstruction and Multi-Shot DWI
4
The Weight of Numbers in Radiology
5









